Medical expert of the article
New publications
Preparations
Lycopida in psoriasis
Last reviewed: 23.04.2024
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
Likopid - a modern drug of the last generation, activating the immune system. Monopreparation with the active component of glucosaminylmuramyl dipeptide, whose prototype, the natural glycopeptide, is the building material of the cell membrane of bacterial agents. When Likopid gets into the body, an imitation of the natural process of the immune response to the entry of pathogenic microorganisms takes place.
Indications of the lycopida in psoriasis
This drug is an immunocorrector and is used for acquired immunodeficiency states:
- chronic infectious-inflammatory diseases of the respiratory tract (in particular, - prevention of ARVI);
- tuberculosis;
- dermatitis and dermatosis, infectious-inflammatory lesions of soft tissues, including post-operative;
- all forms of herpes of arbitrary localization;
- trophic ulcers of different etiology;
- infection with HPV;
- vaginal dysbiosis;
- hepatitis B and C;
- psoriatic lesions of the skin, incl. Complicated.
One of the alleged prerequisites for the emergence of psoriasis is called the disorder of the immune system, and the hypothesis of its viral nature is not excluded. The efficacy of Lycopida in psoriasis is probably due to the properties of glucosaminylmuramyl dipeptide to activate the production of tumor necrosis factor α-factor and, as a consequence, interleukin 1, which occupy a significant position in the development of many autoimmune pathologies. When certain treatment regimens are used, positive immunity correction results can be achieved.
The therapeutic effect of treatment of squamous Lycopidae was achieved in approximately 80% of cases. With effective treatment, by the end of the first week, the appearance of new papules and the growth of old foci ceased, the ecdysis decreased, the regressing stage began, the psoriatic plaques disappeared by the end of the second or third week.
Lycopid is used to treat psoriasis due to its ability to eliminate inflammation, destroy viruses, activate metabolic processes, restore normal blood flow and skin surface. Its bactericidal and fungicidal properties help to withstand secondary infection.
However, the doctors' reviews of Lycopida from psoriasis are mixed. There is an opinion that this medicine can be used only in complex therapy to strengthen the effect of the use of other drugs. Monotherapy with this drug by many doctors is not welcome.
[Release form
Form of release Likopida - tablets with 0.001 g or 0.01 g of glucosaminylmuramyl dipeptide.
Pharmacodynamics
The action of Lycopida is directed to macrophages, it enhances their function of "devouring" microorganisms, toxicity to cells infected with viruses, expression of HLA-DR antigens, production of γ-interferon, interleukin 1, 6, 12, tumor necrosis factor α-factor, colony stimulators. The active component of the drug, binding to the NOD-like intracellular immune receptor, reproduces the natural immune response to attack of pathogenic microorganisms and stimulates innate immunity.
Lycopid activates all types of immune defense: phagocytosis, immune system cells, humoral factors, as well as cytochrome P-450, which catalyzes the cleavage of toxic and other foreign substances.
Pharmacokinetics
Oral (sublingual) reception provides bioavailability of glucosaminylmuramyl dipeptide at the level of 7-13%. The highest concentration in the blood plasma is observed approximately after 1 hour 30 minutes after administration. Half of the dose taken is mainly excreted in the urine for a little over four hours.
Use during pregnancy and lactation is contraindicated.
Dosing and administration
Tablets dissolve under the tongue or taken orally, washed down with a small amount of water. After 30 minutes you can eat.
Adults are treated with tablets containing 0.01 g of the active ingredient. The basic scheme of taking tablets: one piece twice a day for ten days, then the next ten days - one piece once every other day. There are other reception schemes. In severe cases, for example, with psoriatic arthropathy - twice a day for two decades.
The scheme of treatment is appointed by the doctor individually, being guided by the anamnesis of the patient.
Scaly lichen in children under 16 years of age are treated with tablets of 0.001g, they are prescribed one piece, one - three times a day for a decade.
The consequences of exceeding the recommended dose of the drug is not known.
Interactions with other drugs
Together with tetracyclines and sulfonamides is not prescribed.
In combination with antibiotics of cephalosporin, fluoroquinol, penicillin, polyene series, as well as - with antiviral and antifungal agents, enhances their effect.
The combination with enterosorbent and antacid reduces the absorption of the active component of Lycopida, with glucocorticosteroids - lowers the degree of therapeutic effect of Lycopida.
Shelf life
Keep the tablets for not more than 5 years, observing the temperature regime up to 25 ° C.
Attention!
To simplify the perception of information, this instruction for use of the drug "Lycopida in psoriasis" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.
Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.